VRTX · 10-Q · 2026Q3 · Full report
Capital Return Program
VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 32 · Surprise 24 · Matches filing data
Vertex repurchased common stock during the first nine months of 2026, contributing to financing cash outflows alongside the Crinetics acquisition financing.,As of September 30, 2026, $2.5 billion remained available under the share repurchase authorization approved by the Board in May 2025.,The authorization has no expiration date and can be discontinued at any time.,Vertex expects to fund future repurchases with a combination of cash on hand and cash generated from operations.
Key facts
- Vertex had $2.5 billion remaining under the share repurchase program authorized by its Board in May 2025 as of September 30, 2026; the program has no expiration date, may be discontinued at any time and is expected to be funded with cash on hand and operating cash. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -3.3% | Vertex had $2.5 billion remaining under the share repurchase program authorized by its Board in May 2025 as of September 30, 2026; the… |